4.8 Review

Autoreactive T cells in type 1 diabetes

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 8, Pages 2881-2891

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI94549

Keywords

-

Funding

  1. NIH [R01 DK070011]
  2. JDRF [25-2013-268, 17-2011-594, 17-2012-3]
  3. Leona M. and Harry B. Helmsley Charitable Trust [2015PG-T1D052]
  4. Diabetes Research Institute Foundation, Hollywood, Florida

Ask authors/readers for more resources

Type 1 diabetes (T1D) is a chronic autoimmune disease that causes severe loss of pancreatic beta cells. Autoreactive T cells are key mediators of beta cell destruction. Studies of organ donors with T1D that have examined T cells in pancreas, the diabetogenic insulitis lesion, and lymphoid tissues have revealed a broad repertoire of target antigens and T cell receptor (TCR) usage, with initial evidence of public TCR sequences that are shared by individuals with T1D. Neoepitopes derived from post-translational modifications of native antigens are emerging as novel targets that are more likely to evade self-tolerance. Further studies will determine whether T cell responses to neoepitopes are major disease drivers that could impact prediction, prevention, and therapy. This Review provides an overview of recent progress in our knowledge of autoreactive T cells that has emerged from experimental and clinical research as well as pathology investigations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available